Related Experiment Videos
The effects of flurazepam on sleep studies in patients with chronic obstructive pulmonary disease
Abstract:
We studied five male nonobese patients (mean age, 61 years) who had moderate chronic obstructive pulmonary disease (COPD). Each patient underwent three successive nights of systematic monitoring of sleep variables. On nights 2 and 3, patients received placebo and flurazepam (30 mg). Patients were also given flurazepam (15 mg) for seven consecutive nights and underwent sleep monitoring on nights 1 and 7. Two patients exhibited oxygen desaturation during rapid-eye-movement (REM) sleep, both spontaneously and after administration of flurazepam. The three other patients had no nocturnal oxygen desaturation, either spontaneously or after ingestion of flurazepam. We concluded that sleep-induced respiratory abnormalities are not systematically worsened by flurazepam. Flurazepam (15 mg) had no effect on the sleep disturbances of our patients with COPD after seven nights of administration.
Insights
Flurazepam does not worsen sleep-induced respiratory issues in patients with chronic obstructive pulmonary disease (COPD). A 15 mg dose of flurazepam showed no effect on sleep disturbances after seven nights in COPD patients.
Area of Science:
- Pulmonary Medicine
- Sleep Medicine
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) can lead to sleep-related respiratory disturbances.
- The impact of sedative medications on COPD patients' sleep quality and oxygenation requires further investigation.
Purpose of the Study:
- To investigate the effects of flurazepam on sleep-induced respiratory abnormalities in patients with moderate COPD.
- To determine if flurazepam administration exacerbates nocturnal oxygen desaturation in COPD patients.
Main Methods:
- Five male patients with moderate COPD underwent polysomnography.
- Patients received placebo, flurazepam 30 mg, and flurazepam 15 mg over successive nights.
- Sleep variables and oxygen saturation were systematically monitored.
Main Results:
- Two patients experienced oxygen desaturation during REM sleep, both spontaneously and after flurazepam administration.
- The remaining three patients showed no nocturnal oxygen desaturation with or without flurazepam.
- Seven nights of 15 mg flurazepam did not alter sleep disturbances in the studied COPD patients.
Conclusions:
- Flurazepam does not appear to systematically worsen sleep-induced respiratory abnormalities in COPD patients.
- Low-dose flurazepam (15 mg) did not significantly impact sleep disturbances in this COPD cohort after chronic administration.